Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma - ND

Active, not recruiting

• Conditions: orbital lymphoma; MedDRA version: 9.1Level: LLTClassification code 10003899Term: B-cell lymphoma

• Registration Number: EUCTR2007-007799-40-IT
• Lead Sponsor: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12-18
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-primary diffuse large cell B cell Lymphoma / Follicular-centre cell lymphoma
-expression of Antigen CD20
-ocular/periocular confined lesion
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-other subtype of lymphomas than primary diffuse large cell B cell Lymphoma / Follicular-centre cell lymphoma
-no expression of Ag CD20
-widespread diffusion of disease
-age<18
-pregnancy
-lactation
-unstable cardiopathy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified